Skip to main content
. 2019 Mar 28;116(16):7957–7962. doi: 10.1073/pnas.1820989116

Fig. 1.

Fig. 1.

(A) Dose inhibition curves of adult glioma (GBM-0401) and DIPG (DIPG-VI) cell-lines and human NPCs treated with MI-2 and MI-503. IC50 values and World Health Organization (WHO) classification of glioma cell lines shown. IDH, isocitrate dehydrogenase. (B) Western blot of CRISPR/Cas9 gene-edited MEN1-KO GBM-0401 cell lines and controls. KO 1–4 generated with sgRNA targeting MEN1 exon 4. KO 2–2, 2–3, 2–4 generated with sgRNA targeting MEN1 exon 7. WT1–WT4 generated with control sgRNA targeting nonhuman sequence (Renilla luciferase). Parental cell line (PAR) not transduced with sgRNA. (C) Western blot of CRISPR/Cas9 gene-edited MEN1-KO DIPG-VI cell line and controls. KO 1–3 generated with sgRNA targeting MEN1 exon 4. WT3 and WT4 were generated with control sgRNA targeting nonhuman sequence (Renilla luciferase gene). PAR not transduced with sgRNA. (D) Dose-inhibition curves of MEN1 wild-type cells (parental cells and cells transduced with sgRNA targeting Renilla luciferase) and KO cells (transduced with MEN1 targeted sgRNA) treated with MI-2 for 7 d.